Plain-English translation of NCT06335160 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether , a medication normally used to treat parasitic infections, might help improve ulcerative colitis when combined with standard treatment. Researchers want to see if adding this medication to mesalamine (the usual first-line ulcerative colitis treatment) makes a real difference in how patients feel and how their gut heals over 6 months.
Ulcerative colitis is a chronic inflammatory condition that doesn't always respond well enough to standard treatments alone. This trial explores whether the medication, which has immune-modulating properties, could be a safe and affordable addition to help more patients control their symptoms.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups for 6 months. One group will continue their regular mesalamine treatment, while the other group will take the same mesalamine plus the study medication twice daily. Throughout the study, you'll take your assigned treatment for 6 months and likely have follow-up visits to check how you're responding and to monitor for any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Egypt
Sponsor
Tanta University
Enrollment target
~46 participants
Started
April 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.